05:34 PM EDT, 03/27/2024 (MT Newswires) -- Acumen Pharmaceuticals ( ABOS ) on Wednesday filed a registration statement with the US Securities and Exchange Commission covering the potential sale of up to $200 Million of its securities from time to time in one or more offerings.

The filing covers common and preferred stock, debt securities, and warrants.

The company intends to use the proceeds from the sale for working capital, capital expenditures, and general corporate purposes

Shares of the company fell 2.2% in after-hours activity.

Price: 4.01, Change: -0.09, Percent Change: -2.19